Triple-negative breast cancer (TNBC), characterized by the absence or low expression of
estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor …

Due to the lack of definitive hormone receptors, triple negative breast cancer (TNBC)
patients receive little clinical benefit from endocrine or molecular targeted therapies, leading …

Importance The increasing use of neoadjuvant systemic therapy (NST) has led to substantial
pathological complete response rates in patients with initially node-positive, early breast …

Introduction Residual tumor cellularity (RTC) and pathologic complete response (pCR) after
neo-adjuvant chemotherapy (NAC) are prognostic factors associated with improved …

Simple Summary The implementation of precision medicine will revolutionize cancer
treatment paradigms. Notably, this goal is not far from reality: genetically similar cancers can …

Abstract Background 13–15% of breast cancer/BC patients diagnosed as pathological
complete response/pCR after neoadjuvant systemic therapy/NST suffer from recurrence …

Simple Summary Circulating cell-free DNA displays vast potential to capture the entire
genetic landscape of a tumor and to characterize intratumoral heterogeneity, providing a …

This review focuses on neoadjuvant chemotherapy for breast cancer which introduces
practical issues for pathologists, including predicting response, optimising specimen …

Breast cancer continues to be the most diagnosed cancer among women worldwide.
Neoadjuvant chemotherapy is the standard of care for breast cancer patients with locally …

Neoadjuvant Chemotherapy (NAC) in Breast Cancer (BC) has proved useful for the
reduction in tumor burden prior to surgery, allowing for a more extensive breast preservation …